Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $5.75 in the prior trading day, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $5.70, down -0.87%. In other words, the price has decreased by -$0.87 from its previous closing price. On the day, 13.64 million shares were traded. RXRX stock price reached its highest trading level at $5.985 during the session, while it also had its lowest trading level at $5.6.
Ratios:
Our goal is to gain a better understanding of RXRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 4.35. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 21 ’24 when Marriott Tina bought 6,000 shares for $5.78 per share.
Gibson Christopher sold 20,000 shares of RXRX for $154,800 on Nov 13 ’24. The Chief Executive Officer now owns 762,656 shares after completing the transaction at $7.74 per share. On Nov 14 ’24, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $7.35 each. As a result, the insider received 147,000 and left with 762,656 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2216040192 and an Enterprise Value of 1297955968. For the stock, the TTM Price-to-Sale (P/S) ratio is 33.70 while its Price-to-Book (P/B) ratio in mrq is 3.11. Its current Enterprise Value per Revenue stands at 19.912 whereas that against EBITDA is -3.564.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $5.62. The 50-Day Moving Average of the stock is -13.85%, while the 200-Day Moving Average is calculated to be -31.37%.
Shares Statistics:
The stock has traded on average 5.49M shares per day over the past 3-months and 10888590 shares per day over the last 10 days, according to various share statistics. A total of 226.26M shares are outstanding, with a floating share count of 221.60M. Insiders hold about 22.71% of the company’s shares, while institutions hold 79.03% stake in the company. Shares short for RXRX as of 1730332800 were 62427631 with a Short Ratio of 11.36, compared to 1727654400 on 62578756. Therefore, it implies a Short% of Shares Outstanding of 62427631 and a Short% of Float of 24.560000000000002.
